Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,262 Million (Large Cap)
25.00
NA
2.25%
0.25
6.78%
1.32
Revenue and Profits:
Net Sales:
2,390 Million
(Quarterly Results - Mar 2026)
Net Profit:
359 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.0%
0%
10.0%
6 Months
5.67%
0%
5.67%
1 Year
31.25%
0%
31.25%
2 Years
35.25%
0%
35.25%
3 Years
-10.47%
0%
-10.47%
4 Years
1.05%
0%
1.05%
5 Years
-16.91%
0%
-16.91%
Zhejiang Hisun Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-2.03%
EBIT Growth (5y)
22.32%
EBIT to Interest (avg)
2.76
Debt to EBITDA (avg)
3.34
Net Debt to Equity (avg)
0.35
Sales to Capital Employed (avg)
0.76
Tax Ratio
21.59%
Dividend Payout Ratio
40.74%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.18%
ROE (avg)
6.61%
Valuation key factors
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
1.47
EV to EBIT
19.82
EV to EBITDA
8.27
EV to Capital Employed
1.37
EV to Sales
1.52
PEG Ratio
0.04
Dividend Yield
2.06%
ROCE (Latest)
6.91%
ROE (Latest)
5.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
2,390.50
2,626.80
-9.00%
Operating Profit (PBDIT) excl Other Income
301.90
455.90
-33.78%
Interest
16.70
21.60
-22.69%
Exceptional Items
-0.40
1.60
-125.00%
Consolidate Net Profit
358.50
79.40
351.51%
Operating Profit Margin (Excl OI)
126.30%
82.20%
4.41%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -9.00% vs -1.71% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 351.51% vs -51.32% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
10,488.60
9,734.10
7.75%
Operating Profit (PBDIT) excl Other Income
2,079.90
1,814.40
14.63%
Interest
104.90
155.60
-32.58%
Exceptional Items
-223.60
-141.30
-58.24%
Consolidate Net Profit
547.50
591.30
-7.41%
Operating Profit Margin (Excl OI)
105.20%
75.00%
3.02%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 7.75% vs -5.77% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -7.41% vs 709.59% in Dec 2024
About Zhejiang Hisun Pharmaceutical Co., Ltd. 
Zhejiang Hisun Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






